Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors
Journal of Personalized Medicine · 03.03.2026 · 16 (3) · 143
DOI: 10.3390/jpm16030143 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 03.03.2026. Verfasst von Ilaria Poli und 18 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
HER2-positive/hormone-receptor-positive breast cancer represents approximately 10% of all breast cancer cases and constitutes a distinct biological entity with unique therapeutic challenges. The complex crosstalk between HER2 and estrogen receptor signaling pathways contributes to both primary and acquired resistance to anti-HER2 therapies, and the convergence of these pathways on cell cycle regulation, particularly through the cyclin D1-CDK4/6-Rb axis, has provided a compelling rationale for combining CDK4/6 inhibitors with anti-HER2 therapy. This scoping review aimed to map preclinical and clinical evidence evaluating combinations of CDK4/6 inhibitors with HER2-targeted therapy in HER2+/HR+ disease. Eligible sources included preclinical models and clinical studies assessing CDK4/6 inhibitor-based combinations with anti-HER2 therapy, identified through searches of PubMed, Embase, Cochrane Library, Web of Science and ClinicalTrials.gov. Data were charted and synthesized descriptively according to PRISMA-ScR guidelines. Preclinical studies have demonstrated synergistic antitumor activity when CDK4/6 inhibitors are combined with trastuzumab, pertuzumab, or newer HER2-targeted agents across multiple HER2+ breast cancer models. In the metastatic setting, phase II trials including MonarcHER and PATRICIA II have shown encouraging efficacy signals, while the phase III PATINA trial demonstrated a clinically meaningful 15.2-month progression-free survival benefit with palbociclib plus anti-HER2 therapy and endocrine therapy. In the neoadjuvant setting, trials including NA-PHER2 and MUKDEN-01 demonstrated marked Ki67 suppression and promising pathologic responses, supporting the exploration of chemotherapy de-escalation strategies. Despite these advances, key challenges remain including the identification of predictive biomarkers, optimal treatment sequencing, and the integration of emerging HER2-targeted agents such as trastuzumab deruxtecan. Novel CDK4/6 inhibitors including dalpiciclib and next-generation agents are expanding therapeutic options, while combination strategies incorporating CDK7 inhibition represent future therapeutic frontiers. The evolving landscape of HER2+/HR+ breast cancer treatment increasingly emphasizes precision medicine approaches that leverage cell cycle control mechanisms to overcome resistance and improve patient outcomes across all disease stages.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
- Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
- Liquid Biopsy Platform, Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY 10021, USA.
- Precision Medicine in Breast Cancer Unit, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
- Medical Oncology Unit, Ospedale Isola Tiberina-Gemelli Isola, 00186 Rome, Italy.
ORCID-Profile: Ilaria Poli, Gaia Rachele Oliva, Angelachiara Rotondi, Giorgia Arcuri, Antonella Palazzo, Armando Orlandi
Zitieren
APA
Poli, I., Oliva, G. R., Mongelli, G., Rotondi, A., Frescura, V., Arcuri, G., Garufi, G., Pontolillo, L., Mastrantoni, L., Di Monte, E., Maliziola, N., Fucile, M. A., Salvatori, F., Mondello, R., Palazzo, A., Fabi, A., Bria, E., Tortora, G., & Orlandi, A. (2026). Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors. Journal of Personalized Medicine, 16(3), 143. https://doi.org/10.3390/jpm16030143
Vancouver
Poli I, Oliva GR, Mongelli G, Rotondi A, Frescura V, Arcuri G, et al. Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors. Journal of Personalized Medicine. 2026;16(3):143. doi:10.3390/jpm16030143
BibTeX
@article{Poli2026,
author = {Poli, Ilaria and Oliva, Gaia Rachele and Mongelli, Ginevra and Rotondi, Angelachiara and Frescura, Valentina and Arcuri, Giorgia and Garufi, Giovanna and Pontolillo, Letizia and Mastrantoni, Luca and Di Monte, Elena and Maliziola, Noemi and Fucile, Maria Antonia and Salvatori, Francesca and Mondello, Rita and Palazzo, Antonella and Fabi, Alessandra and Bria, Emilio and Tortora, Giampaolo and Orlandi, Armando},
title = {Next Frontier in HER2+/HR+ Breast Cancer: Leveraging Cell Cycle Control with CDK4/6 Inhibitors},
journal = {Journal of Personalized Medicine},
year = {2026},
volume = {16},
number = {3},
pages = {143},
doi = {10.3390/jpm16030143}
}
EUVIMED